Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Measured evidence
Company news sentiment
LLY news sentiment
Eli Lilly and Company
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score54Neutral is 50
Balanced news tone
37/100 evidence confidence
88% direct company focus
28 current stories across 16 publishers
Current company news
Balanced news tone
The score uses 28 current company stories from 16 publishers.
Observed headline tone58/100
→
Published 30-day score54/100
Latest source headline
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
finance.yahoo.com · 12 Aug 2026 11:30
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
28 current stories are mapped specifically to LLY.
The score uses 16 publishers rather than depending on one outlet.
The current stories agree at 85/100.
What limits the score
No major limit stands out.
54/100
News scoreBalanced news tone
37/100
Confidencethin evidence
88%/100
Company news28 company stories
85/100
Story agreement15/100 difference
News history
Daily score and story count over 30 days
16 Jul31 Jul14 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence18
0.906 after freshness weightingSource breadth100
16 independent publishersCompany relevance88
share tied directly to this companyFreshness52
recency-weighted evidenceAgreement85
how closely stories agreePublisher mix64
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
News tone and price action are not far from neutral.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202645MXN 20245.01+1.7%
31 Jul 202651MXN 19900.0-4.4%
24 Jul 202651MXN 20820.85+0.4%
17 Jul 202653MXN 20736.24+0.1%
10 Jul 202651MXN 20708.48-1.5%
03 Jul 202651MXN 21029.0-0.5%
26 Jun 202650MXN 21142.75+10.4%
19 Jun 202651MXN 19148.82-2.6%
News subjects
What is shaping the score
Market update5013 stories · 46%
Earnings687 stories · 25%
Regulatory and legal527 stories · 25%
Analyst action501 stories · 4%
Source mix
Where the evidence comes from
finance.yahoo.com598 stories · 29%
simplywall.st594 stories · 14%
nasdaq.com622 stories · 7%
Trefis502 stories · 7%
Stocktwits601 stories · 4%
seekingalpha.com501 stories · 4%
MarketBeat501 stories · 4%
Recurring subjects
Subjects appearing most often
Pharma8Clinical Trials5Regulation4Fda Approval4Earnings4Biotech3Healthcare2Financial Results2Earnings Per Share2Price Target1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
19 Jun50 neutral14 Aug 01:37
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Aug 01:37 | 54 | +0 | 57/100 (-5) | 67 (-1) | Measured |
| 12 Aug 23:59 | 54 | -2 | 62/100 (+3) | 68 (+11) | Measured |
| 11 Aug 23:59 | 56 | +2 | 59/100 (+5) | 57 (+11) | Measured |
| 10 Aug 23:59 | 54 | -1 | 54/100 (+10) | 46 (+14) | Measured |
| 09 Aug 23:59 | 55 | +2 | 44/100 (-1) | 32 (0) | Measured |
| 08 Aug 23:59 | 53 | +8 | 45/100 (+8) | 32 (+1) | Measured |
| 07 Aug 23:59 | 45 | -5 | 37/100 (+6) | 31 (+2) | Provisional |
| 05 Aug 23:59 | 50 | +0 | 31/100 (0) | 29 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
finance.yahoo.comDirect company coverageStored article
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro
Antibody Drug ConjugatesBiotechCancerClinical Trials
- Published
- 12 Aug 2026 11:30
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.1% · 1.6d old
- Duplicates
- 1 consolidated
#250Tone
seekingalpha.comDirect company coverageStored article
Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots
[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c
FdaPharmaRegulation
- Published
- 12 Aug 2026 09:41
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 7.4% · 1.7d old
- Duplicates
- 1 consolidated
#350Tone
finance.yahoo.comDirect company coverageStored article
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors an
Clinical TrialsFda ApprovalHealthcarePharmaRegulation
- Published
- 12 Aug 2026 09:30
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 9.5% · 1.7d old
- Duplicates
- 1 consolidated
#450Tone
MarketBeatDirect company coverageScored from headlineSource lookup
Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock
- Published
- 11 Aug 2026 21:19
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.8% · 2.2d old
- Duplicates
- 1 consolidated
#535Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial
Clinical TrialsFinancial ResultsLawsuitNet IncomeObesity TreatmentPharma
- Published
- 11 Aug 2026 12:44
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 11.4% · 2.5d old
- Duplicates
- 1 consolidated
#650Tone
finance.yahoo.comDirect company coverageStored article
Veeva Vault CRM Selected by Eli Lilly and Company
PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. "We are excited to expand our strategic work with Veeva by moving to Vault CRM," said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly.
BiotechCrmPharma
- Published
- 11 Aug 2026 11:03
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.7% · 2.6d old
- Duplicates
- 1 consolidated
#767Tone
nasdaq.comDirect company coverageStored article
Eli Lilly's Foundayo Wins UK Approval
(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data
BiotechDiabetesEarningsFda ApprovalPharmaRegulation
- Published
- 11 Aug 2026 07:30
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 14.2% · 2.8d old
- Duplicates
- 1 consolidated
#850Tone
nasdaq.comDirect company coverageStored article
Why Eli Lilly Topped the Market Today
Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight
EuropeMarketsObesity TreatmentsPharmaRegulation
- Published
- 10 Aug 2026 22:13
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.9% · 3.1d old
- Duplicates
- 1 consolidated
#957Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portf
CLINICAL-TRIALSClinical TrialsFDA-APPROVALFda ApprovalHEALTHCAREHealthcare
- Published
- 08 Aug 2026 21:16
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6.6% · 5.2d old
- Duplicates
- 1 consolidated
#1057Tone
finance.yahoo.comDirect company coverageStored article
BofA points to the Eli Lilly market that could outsize the U.S.
Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came out of the earnings call pointing to a different number. The bank thinks the obesity market outside the United States could eventually surpass U.S. sales of the same drugs. For anyone holding LLY or considering it, that international call is worth a closer look. Why Bank of America raised its Eli Lill
Drug DevelopmentEarningsEarnings EstimateObesityPharmaPrice Target
- Published
- 08 Aug 2026 18:33
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.1% · 5.3d old
- Duplicates
- 1 consolidated
#1185Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly and Company Q2 Earnings Call Highlights
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 billion and adjusted earnings-per-share guidance to $35.50–$36.50. Demand for obesity medicines remained strong, with U.S. obesity prescriptions up 78% year over year. Lilly said the Medicare GLP-1 Bridge Program expanded coverage for its obesity medicines by 35%, while Foundayo's launch continued gaining prescrib
Business DevelopmentEarningsEarnings Per ShareGuidanceObesity MedicinesPipeline Expansion
- Published
- 08 Aug 2026 16:04
- News subject
- Earnings
- Why this score
- Guidance raised, Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 16.5% · 5.4d old
- Duplicates
- 1 consolidated
#1250Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. This new product could help Eli Lilly extend its lead over its biggest competitor in this space, Novo Nordisk (NYSE: NVO). Here's the rundown. Best-in-class efficacy In a phase 3 study, retatrutide posted an average
Clinical TrialsEarningsEarnings Per ShareFda ApprovalFinancial ResultsPharma
- Published
- 07 Aug 2026 22:50
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.8% · 6.1d old
- Duplicates
- 1 consolidated
#1357Tone
simplywall.stDirect company coverageScored from headlineSource lookup
Will Strong Q2 Results and Higher 2026 Outlook Change Eli Lilly's (LLY) Narrative?
- Published
- 07 Aug 2026 08:17
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5% · 6.7d old
- Duplicates
- 1 consolidated
#1450Tone
BenzingaDirect company coverageScored from headlineSource lookup
$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
- Published
- 05 Aug 2026 07:17
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.3% · 8.8d old
- Duplicates
- 1 consolidated
#1550Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup
Eli Lilly's obesity momentum faces another earnings test (LLY:NYSE)
- Published
- 04 Aug 2026 22:12
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3% · 9.1d old
- Duplicates
- 1 consolidated
#1650Tone
FinancialContentDirect company coverageScored from headlineSource lookup
What To Expect From Eli Lilly’s (LLY) Q2 Earnings
- Published
- 04 Aug 2026 10:34
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.4% · 9.6d old
- Duplicates
- 1 consolidated
#1750Tone
Stocks Down UnderDirect company coverageScored from headlineSource lookup
Eli Lilly’s (NYSE:LLY) Weight-Loss Drugs Could Bring In $13 Billion This Quarter- but Is It Enough?
- Published
- 03 Aug 2026 00:34
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2% · 11.0d old
- Duplicates
- 1 consolidated
#1850Tone
simplywall.stDirect company coverageScored from headlineSource lookup
Eli Lilly (LLY) Invests $750 Million With Resilience To Expand U.S. Drug Manufacturing
- Published
- 31 Jul 2026 13:36
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 13.5d old
- Duplicates
- 1 consolidated
#1950Tone
TradingKeyDirect company coverageScored from headlineSource lookup
Eli Lilly and Co Stock (LLY) Moved Down by 4.09% on Jul 30: Key Drivers Unveiled
- Published
- 31 Jul 2026 12:14
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 13.6d old
- Duplicates
- 1 consolidated
#2050Tone
TrefisDirect company coverageScored from headlineSource lookup
How Much Eli Lilly (LLY) Are You Really Betting On?
- Published
- 30 Jul 2026 19:37
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 14.3d old
- Duplicates
- 1 consolidated
#2150Tone
Market sourceDirect company coverageScored from headlineSource lookup
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
- Published
- 29 Jul 2026 08:37
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 15.7d old
- Duplicates
- 1 consolidated
#2250Tone
TrefisDirect company coverageScored from headlineSource lookup
Does Eli Lilly Stock Offer More Than Just Momentum?
- Published
- 28 Jul 2026 14:14
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 16.5d old
- Duplicates
- 1 consolidated
#2350Tone
GuruFocusDirect company coverageScored from headlineSource lookup
Eli Lilly's New Obesity Drug (LLY) Shows Promising Phase 3 Resul
- Published
- 24 Jul 2026 04:07
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 20.9d old
- Duplicates
- 1 consolidated
#2450Tone
GuruFocus.comDirect company coverageScored from headlineSource lookup
Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing
- Published
- 23 Jul 2026 17:14
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 21.3d old
- Duplicates
- 1 consolidated
#2550Tone
simplywall.stDirect company coverageScored from headlineSource lookup
The Bull Case For Eli Lilly (LLY) Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas
- Published
- 21 Jul 2026 07:37
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 23.7d old
- Duplicates
- 1 consolidated
#2660Tone
StocktwitsDirect company coverageScored from headlineSource lookup
Eli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Months
- Published
- 20 Jul 2026 02:07
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 25.0d old
- Duplicates
- 1 consolidated
#2750Tone
thestreet.comDirect company coverageScored from headlineSource lookup
UBS strongly resets Lilly stock target
- Published
- 17 Jul 2026 07:37
- News subject
- Analyst action
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 27.7d old
- Duplicates
- 1 consolidated
#2867Tone
simplywall.stDirect company coverageScored from headlineSource lookup
Eli Lilly (LLY) Wins Full FDA Approval For Retevmo In RET Fusion Tumors
- Published
- 15 Jul 2026 08:58
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.2% · 29.7d old
- Duplicates
- 1 consolidated
Earlier company news
LLY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Jun
22
2026
MoomooArchivedLegacy headline · tone unscoredLegacy source lookup
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Hold Rating, Raises Target Price to $1,135
- Published
- 22 Jun 2026 21:37
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
simplywall.stArchivedLegacy headline · tone unscoredLegacy source lookup
Eli Lilly (LLY) Teams Up With BioArctic On A New Neurodegeneration Therapy
- Published
- 22 Jun 2026 12:31
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
20
2026
CoinGeckoArchivedLegacy headline · tone unscoredLegacy source lookup
Eli Lilly Stock Price: LLY Stock Chart, Market Cap & News Today
- Published
- 20 Jun 2026 17:22
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
19
2026
ChartMillArchivedLegacy headline · tone unscoredLegacy source lookup
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentals
- Published
- 19 Jun 2026 16:26
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
19
2026
Market sourceArchivedLegacy headline · tone unscoredLegacy source lookup
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
- Published
- 19 Jun 2026 09:57
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Mar
04
2025
Market sourceArchivedNeutral tone
Eli Lilly and Company (LLY): Among the Best Stocks To Invest In According to Billionaires
- Published
- 4 Mar 2025 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to LLY, but the headline and available text are not mainly about Eli Lilly and Company. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of LLY sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.